Dyck

: 1993 APPAL Somit; Zolpidem Gador. Somit. Hypnotic selectivity. The class of the future…today. The chemical class of the future. Somit (Zolpidem Gador) selectively joins itself with the Omega-1 receptors, being the first hypnotic selective agent that is not a benzodiazepine. Somit (Zolpidem Gador) re-establishes the architecture of sleep: it does not diminish and actually promotes the paradoxical sleep (REM). Conserves or augments the duration of deep sleep. Somit (Zolpidem Gador) respects the cognitive functions, particularly attention and memory. Somit (Zolpidem Gador) does not induce residual effects or alterations of motor activity and physical performance. Somit (Zolpidem Gador) does not develop tolerance, rebound syndrome or abstinence syndrome., Zolpidem, Gador, Box of Somit shown with tablets, along with a depiction of chemical models.

: 1993 APPAL Zoloft; Coming soon. Approved by the FDA. Zoloft. Sertraline. Drug investigated and developed by Pfizer. It will change the face of depression. Available in the United States, Canada, England, Belgium and other countries., Sertraline, Pfizer, Sun with a smiley face on it.

: 1993 APPAL Zoloft; Now in Argentina. Zoloft. Setraline. Drug investigated and developed by Pfizer. Change the face of depression. Effective even in patients that did not respond to other anti-depressants. Without cardiotoxic effects. Without sedative effects. Simple dosage (once a day). Available in the United States, the United Kingdom, Spain and other countries. Approved by the FDA., Sertraline, Pfizer, Sun with a smiley face on it. Grid with several sad faces on it surrounding a yellow square with a smiley face on it.